Effects of tadalafil on erectile dysfunction in men with diabetes

Diabetes Care

Volumn 25, Issue 12, 2002, Pages 2159-2164

  De Tejada, Iñigo Sáenz ^a   Anglin, Greg ^b   Knight, James R ^b   Emmick, Jeffrey T ^b  

^a Development and Application of Composite Materials   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TADALAFIL; ANTIHYPERTENSIVE AGENT; CARBOLINE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; PHOSPHODIESTERASE INHIBITOR; PLACEBO;

ADULT; ANAMNESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; HEADACHE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PENIS ERECTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; IMPOTENCE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ANTIHYPERTENSIVE AGENTS; CARBOLINES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PLACEBOS; TREATMENT OUTCOME;

EID: 1842852557     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.12.2159     Document Type: Article

References (22)

1. Metro MJ, Broderick GA: Diabetes and vascular impotence: does insulin dependence increase the relative severity? Int J Impot Res 11:87-89, 1999
2. Lehman TP, Jacobs JA: Etiology of diabetic impotence. J Urol 129:291-294, 1983
3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 151:54-61, 1994
4. Klein R, Klein BE, Lee KE, Moss SE, Cruickshanks KJ: Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 19:135-141, 1996
5. Buvat J, Lemaire A, Buvat-Herbaut M, Fourlinnie JC, Racadot A, Fossati P: Hyperprolactinemia and sexual function in men. Horm Res 22:196-203, 1985
6. McCulloch DK, Young RJ, Prescott RJ, Campbell IW, Clarke BF: The natural history of impotence in diabetic men. Diabetologia 26:437-440, 1984
7. Diabetes estimates: 2025 [article online], 2001. World Health Organization. Available from http://www.who.int/ncd/dia/databases0.htm. Accessed 26 March 2001
8. McKinlay JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 12 (Suppl. 4):S6-S11, 2000
9. Aytac IA, McKinlay JB, Krane RJ: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84:50-56, 1999
10. Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA 281:421-426, 1999
11. Price DE, Gingell JC, Gepi-Attee S, Wareham K, Yates P, Boolell M: Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. Diabet Med 15:821-825, 1998
12. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J: Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170:843-850, 1990
13. Burnett AL: Nitric oxide in the penis: physiology and pathology. J Urol 157:320-324, 1997
14. Sáenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 320:1025-1030, 1989
15. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC: On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13:2-9, 2001
16. Epidemiology of severe hypoglycemia in the diabetes control and complications trial: the DCCT Research Group. Am J Med 90:450-459, 1991
17. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A: The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile function. Urology 49:822-830, 1997
18. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH: Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 54:346-351, 1999
19. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, Polak J, Wang RZ, Ferguson K, Block C, Haas C: Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 50:1016-1026, 1997
20. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB: Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 163:460-463, 2000
21. Tanner FC, Noll G, Boulanger CM, Luscher TF: Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries: role of scavenger receptor and endothelium-derived nitric oxide. Circulation 83:2012-2020, 1991
22. Rosenfeld ME: Oxidized LDL affects multiple atherogenic cellular responses. Circulation 83:2137-2140, 1991